Combating hematopoietic and hepatocellular abnormalities resulting from administration of cisplatin: role of liver targeted glycyrrhetinic acid nanoliposomes loaded with amino acids

Pharm Dev Technol. 2022 Nov;27(9):925-941. doi: 10.1080/10837450.2022.2129687. Epub 2022 Oct 6.

Abstract

The effectiveness of cisplatin in cancer treatment renders its use vital to clinicians. However, the accompanying side effects as cachexia, emesis and liver damage necessitate the use of a dietary supplement which is capable of hindering such undesirable complications. The branched chain amino acids as well as glutamine and arginine have been proven to be effective nutritional co-adjuvant therapeutic agents. Furthermore, new pharmaceutical approaches encompass designing organ-targeted nanoformulations to increase the medicinal efficacy. Therefore, the aim of the present study was to investigate the beneficial effects of liver-targeted amino acids-loaded nanoliposomes in counteracting the adverse hematopoietic and hepatic complications associated with cisplatin. Results revealed the use of the combination of two nanoliposomal formulations (one loading leucine + isolecuine + valine, and the other loading glutamine and arginine) given orally at a dose of 200 mg/kg for twelve days was effective against cisplatin-induced toxicities represented by improvement in the complete blood picture parameters, decrease in the serum hepatic enzymes levels, amelioration of the hepatic oxidative stress and cellular energy imbalance along with reduction in the histopathological abnormalities. It can be concluded that amino acids loaded nanoliposomes could be considered a new strategy in preventing cisplatin's adverse effects.

Keywords: Cisplatin; amino acids; liposomes; liver damage; nanoparticles.

MeSH terms

  • Amino Acids
  • Arginine
  • Carcinoma, Hepatocellular*
  • Cisplatin
  • Glutamine
  • Glycyrrhetinic Acid*
  • Humans
  • Liver Neoplasms*

Substances

  • Cisplatin
  • Amino Acids
  • Glutamine
  • Glycyrrhetinic Acid
  • Arginine